The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Roitman A.P.

Fedorova T.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Ivanova E.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Bugrov A.V.

Department of clinical laboratory diagnostics, Russian medical Academy of postgraduate education of the Russian Federation, Moscow, Russia

Dolgov V.V.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet"

The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients

Authors:

Roitman A.P., Fedorova T.A., Ivanova E.A., Bugrov A.V., Dolgov V.V.

More about the authors

Journal: Laboratory Service. 2018;7(4): 5‑10

DOI: 10.17116/labs201870415

Read: 12242 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF METABOLISM DISORDERS, INFLAMMATION, MYOCARDIAL INJURY IN DEVELOPMENT CHRONIC HEART FAILURE IN METABOLIC SYNDROME PATIENTS
THE ROLE OF METABOLISM DISORDERS, INFLAMMATION, MYOCARDIAL INJURY IN DEVELOPMENT CHRONIC HEART FAILURE IN METABOLIC SYNDROME PATIENTS

To cite this article:

Roitman AP, Fedorova TA, Ivanova EA, Bugrov AV, Dolgov VV. The role of metabolism disorders, inflammation, myocardial injury in development chronic heart failure in metabolic syndrome patients. Laboratory Service. 2018;7(4):5‑10. (In Russ.)
https://doi.org/10.17116/labs201870415

Подписка 2025-2 (Laboratory Service)
МСФ на ЯМ
Использование инфографики авторами научных работ
Mediasphera_Net
Close metadata
Recommended articles:
Skin alte­rations as possible clinical markers of diabetes mellitus and meta­bolic syndrome. Russian Journal of Preventive Medi­cine. 2024;(7):101-107
Cognitive impairments and emotional diso­rders and their correction in peri­menopausal women. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):48-53
Treatment of atopic dermatitis considering asse­ssment of neurotransmitters in blood. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(4):368-376
Fore­nsic characteristic of sudden death cases in subjects with meta­bolic syndrome. Fore­nsic Medi­cal Expe­rtise. 2024;(4):54-57
Evaluation of clinical effi­cacy and effi­ciency of new anti­coagulants and sodium-glucose cotransporter 2 inhi­bitors in patients with coro­nary artery disease and concomitant cardiovascular diseases. Medi­cal Technologies. Asse­ssment and Choice. 2024;(3):115-123
Meta­bolic syndrome in clinical psychiatric practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):13-20
Stru­ctural, morphological and functional changes of diaphragm in patients with chro­nic heart failure. Russian Journal of Anesthesiology and Reanimatology. 2024;(5):88-95
Predictors of effe­ctive complex physiotherapy in patients with skin invo­lution. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):11-17
Complex physiotherapeutic technologies for various diseases. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):18-23
Modern scientific and practical approaches to searching for biomarkers of aging. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2024;(3):46-52

The information at the article is about the role of laboratory markers of inflammation (high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), myocardial damage (high-sensitivity troponins (hsTn), and metabolic myocardial disorders (leptin, adiponectin, apolipoprotein A (apoA), apolipoprotein B (apoB) in the pathogenesis and diagnosis of chronic heart failure (CHF) in patients with metabolic syndrome and without it. Metabolic syndrome may cause various systemic and local effects, many of it plays the important role in myocardial changes and CHFs progression. The study of these markers is important for understanding their pathogenesis significance in the development of CHF, diagnosis, management, prognosis and adequate therapy.

Keywords:

chronic heart failure
metabolic syndrome
biomarkers

Authors:

Roitman A.P.

Fedorova T.A.

Nauchnyĭ tsentr akusherstva, ginekologii i perinatologii im. akad. V.I. Kulakova, Moskva

Ivanova E.A.

Pirogov Russian National Research Medical University, Moscow, Russia

Bugrov A.V.

Department of clinical laboratory diagnostics, Russian medical Academy of postgraduate education of the Russian Federation, Moscow, Russia

Dolgov V.V.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet"

List of references:

  1. Won H, Kang S-M, Shin MJ, et al. Plasma Adiponectin Concentration and Its Association with Metabolic Syndrome in Patients with Heart Failure. Yonsei Medical Journal. 2012;53(1):91-98. https://doi.org/10.3349/ymj.2012.53.1.91
  2. Belenkov YuN, Mareev VYu. Pervie rezultat nacionalnogo epidemiologichescogo issledovaniya bolnych HSN v realnoy practice. EPOHA-O-HSN. Serdechnaya nedostatochnost. 2003;4(3). (In Russ.)
  3. Drapkina OM, Ivashkin BT, Korneeva ON. Klinicheskie varianty metabolicheskogo sindroma. M.:MIA, 2012. (In Russ.)
  4. Andreassen AK, Nordøy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol. 1998;81(5):604-608. https://doi.org/10.1016/s0002-9149(97)00972-7
  5. Petersen JW, Felker M. Inflammatory Biomarkers in Heart Failure. Congestive Heart Failure. 2006;12(6):324-328. https://doi.org/10.1111/j.1527-5299.2006.05595.x
  6. Kocheruga TN, Makarevich PI, Ovchinnikov AG., Zhigunova LV. Circulating factors associatedwith metabolic disorders in patients with post-infarction heart failure. Serdechnaya nedostatochnost. 2013;14(78):191-199. (In Russ.)
  7. Coffman E, Richmond-Bryant J. Multiple biomaker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Population Health Metrics. 2015;13(7):1-15. https://doi.org/10.1186/s12963-015-0041-5
  8. Bozkurt B, SB, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats // Circulation. 1998;97:1382-1391. https://doi.org/10.1161/01.cir.97.14.1382
  9. Levine B, Kalman J, Mayer I, et al. Elevated circulating level of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine. 1990;323(4):236-241. https://doi.org/10.1056/nejm199007263230405
  10. Anker S, Swan JW, Volterrani M, et al. The influence of muscle mass strength and fatiguability and blood flow on exercise capacity in cachectic and non cachectic patients with chronic HF. European Heart Journal. 1997;18(2):259-269. https://doi.org/10.1093/oxfordjournals.eurheartj.a015229
  11. Secchierro P, Corallini F, Ceconi C, et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLOS One. 2009;4(2):1-6. https://doi.org/10.1371/journal.pone.0004442
  12. Osmancik P, Herman D, Stros P, et al. Changes and prognostic impact of apoptotic and inflammatory cytokines in patients treated with cardiac resynchronization therapy. // Cardiology. 2013;124(3):190-8. Epub 2013 Mar 12. https://doi.org/10.1159/000346621
  13. Krikunova OV, Vasyuk YuA, Viskov RV, et al. Significance of troponin tests for differential diagnosis and prediction in heart failure. Serdechnaya nedostatochnost. 2015;16(4):254-260. (In Russ.) https://doi.org/10.18087/rhfj.2015.4.2122
  14. Nagarajan V, Hernadez AV, Tang WH, Prognostic value of cardiac troponin in chronic stable heart failure: a systematic rewiew. Heart. 2012;98(24):1778-1786. https://doi.org/10.1136/heartjnl-2012-301779
  15. Rubin J, Matsushita K, Ballantyne CM, et al. Chronic hyperglycemia and subclinical myocardial injury. // J Am Coll Cardiol. 2012; 31;59(5):484-9. https://doi.org/10.1016/j.jacc.2011.10.875
  16. Fukuta H, Ohte N, Wakami K, et al. Relation of Plasma Levels of Adiponectin to Left Ventricular Diastolic Dysfunction in Patients Undergoing Cardiac Catheterization for Coronary Artery Disease. The American Journal of Cardiology. 2011;108(8):1081-1085. https://doi.org/10.1016/j.amjcard.2011.06.005
  17. Fujioka D, Kawabata K, Saito Y, et al. Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. American Journal of Physiology-Heart and Circulatory Physiology. 2006;290(6):H2409-H2416. https://doi.org/10.1152/ajpheart.00987.2005
  18. Iwaoka M, Obata J, Abe M et al. Association of Low Serum Levels of Apolipoprotein A-I With Adverse Outcomes in Patients With Nonischemic Heart Failure. Journal of Cardiac Failure. 2007;13(4):247-253. https://doi.org/10.1016/j.cardfail.2007.01.007
  19. Giamouzis G, Butler J. Relationship Between Heart Failure and Lipids: The Paradigm Continues to Evolve. Journal of Cardiac Failure. 2007;13(4):254-258. https://doi.org/10.1016/j.cardfail.2007.03.009
  20. Ingelsson E, Arnlov J, Sudstrom J et al. Novel Metabolic Risk Factors for Heart Failure. Journal of the American College of Car足di足o足lo足gy. 2005;46(11):2054-2016. https://doi.org/10.1016/j.jacc.2005.07.059
  21. Borja MS, Hammerson B, Tang C, et al. Apolipoprotein A-I exchange is impaired in metabolic syndrome patients asymptomatic for diabetes and cardiovascular disease. PLoS One. 2017 Aug 2;12(8):e0182217. eCollection 2017. https://doi.org/10.1371/journal.pone.0182217
  22. Lim Y, Yoo S, Lee SA, et al. Apolipoprotein B is related to Me足ta足bo足lic Syndrome independently of Low Density Lipoprotein Cho足lesterol in patients type 2 Diabetes. Endicrinology and metabolism. 2015;30(2):208-215. https://doi.org/10.3803/enm.2015.30.2.208
  23. Lind L, Vessby B, Sundstrom J. The Apolipoprotein B/AI ratio and the Metabolic Syndrome independently predict risk for myocardial infarction in middle-aged men. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(2):406-410. https://doi.org/10.1161/01.atv.0000197827.12431.d0

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.